drugset / Trial / NCT04891237

Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen

NCT04891237 ↗

Phase 3 Recruiting 180 enrolled Inmunotek S.L.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive

Timeline

Start
2021-06-14
Primary completion
2026-01
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MG01 Protein / enzyme biologic 10000 unknown Subcutaneous
Subject MG01 Protein / enzyme biologic 30000 unknown Subcutaneous
Subject T517 Protein / enzyme biologic 10000 unknown Subcutaneous